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ABSTRACT 
Introduction 
Frailty is highly prevalent in adults with chronic kidney disease (CKD) and is associated with 
adverse health outcomes including falls, poorer health-related quality of life (HRQOL), 
hospitalisation and mortality. Low physical activity and muscle wasting are important 
contributors to physical frailty in adults with CKD. Exercise training may improve physical 
function and frailty status leading to associated improvements in health outcomes, including 
HRQOL. The EX-FRAIL CKD trial aims to inform the design of a definitive randomised 
controlled trial (RCT) that investigates the effectiveness of a progressive, multi-component 
home-based exercise programme in pre-frail and frail older adults with CKD. 
 
Methods and Analysis 
The EX-FRAIL CKD trial is a two-arm parallel group pilot RCT. Participants categorised as pre-
frail or frail, following Frailty Phenotype assessment, will be randomised to receive exercise 
or usual care. Participants randomised to the intervention arm will receive a tailored 12-
week exercise programme, which includes weekly telephone calls to advise on exercise 
progression. Primary feasibility outcome measures include rate of recruitment, intervention 
adherence, outcome measure completion and participant attrition. Semi-structured 
interviews with a purposively selected group of participants will inform the feasibility of the 
randomisation procedures, outcome measures and intervention. Secondary outcome 
measures include physical function (walking speed and Short Physical Performance Battery), 
frailty status (Frailty Phenotype), fall concern (Falls Efficacy Scale-International tool), 
activities of daily living (Barthel Index), symptom-burden (Palliative Care Outcome Scale-
Symptoms RENAL) and HRQOL (Short Form-12v2).  
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Ethics and Dissemination 
Ethical approval was granted by a National Health Service (NHS) Regional Ethics Committee 
and the NHS Health Research Authority. The study team aim to publish findings in a peer-
reviewed journal and present the results at relevant national and international conferences. 
A summary of findings will be provided to participants, a local kidney patient charity and the 
funding body. 
 
Trial Registration: ISRCTN87708989. 
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STRENGTHS AND LIMITATIONS OF THIS STUDY 
 A validated frailty assessment will be used to determine suitability for randomisation 
ensuring that only pre-frail and frail participants receive the intervention. 
 The exercise programme is delivered in a graded and progressive manner with the use 
of weekly participant telephone calls to review progress. 
 A nested qualitative study will explore the acceptability of the randomisation 
procedures, outcome measures and intervention to participants. 
 Semi-structured interviews will be completed by a researcher involved in delivery of the 
study intervention. 
 Patients that decline study enrolment will not be offered the opportunity to participate 
in the qualitative study. 
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INTRODUCTION 
Frailty is the consequence of a cumulative decline in multiple physiological systems 
associated with ageing [1]. This results in a state of increased vulnerability to 
disproportionate changes in health status when exposed to seemingly minor insults, such as 
an infection or fall [1]. Frailty, and its precursor pre-frailty, are associated with an increased 
risk of falls, hospitalisation, worsening disability and death [2]. The pathophysiological 
process inherent to chronic kidney disease (CKD), including, though not limited to, uraemia, 
anabolic hormone dysregulation, increased inflammatory burden, metabolic acidosis and 
cellular senescence, appear to hasten the decline from fitness to frailty [3]. This is to such an 
extent that the prevalence of frailty in CKD, particularly by the time of dialysis initiation, is 
considerably greater than in the community-dwelling older adult population [4,5]. 
Importantly, as in the general older population, patients with CKD and frailty have worse 
outcomes than their non-frail counterparts. Frailty is independently linked with adverse 
clinical outcomes in all stages of CKD, including an increased risk of worse health-related 
quality of life (HRQOL) [6,7], falls [8], hospitalisation and mortality [9-11].  
 
Low physical activity and associated muscle wasting are important contributors to physical 
frailty [3]. Physical activity is low in patients with advanced CKD [12] and muscle wasting is 
pronounced prior to the commencement of dialysis [13]. Increased physical activity levels in 
those with CKD and pre-frailty/frailty may mitigate this muscle wasting. Exercise training has 
been shown to improve physical fitness and HRQOL in CKD populations [14,15]. However, 
patients living with frailty are typically poorly represented in interventional studies, often 
due to concerns that drop-out rates, adverse events or intervention tolerability may be 
affected [16,17]. Studies that have explored the use of exercise training in frail older adults 
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have demonstrated benefits in terms of ‘falls, mobility, balance, functional ability, muscle 
strength and body composition’ [18]. However, the optimum exercise programme has not 
been established [18]. Regardless, exercise programmes that are effective for frail older 
adults may not meet the needs of patients living with frailty and CKD, who are more likely to 
be frail at a younger age [10], report considerable symptom burden [19] and have high 
health care utilisation [20].  
 
Many exercise programmes used in studies involving participants with CKD have been 
performed under supervision within hospital or other facilities [14,15], circumstances that 
can be challenging to implement in clinical practice considering financial and staffing 
constraints. Furthermore, travel for exercise sessions may be onerous for frail individuals 
with CKD who often report higher levels of fatigue [6]. Home-based exercise programmes 
may be less burdensome and more convenient, allowing patients to incorporate physical 
activity into their daily lives leading to longer term adoption and maintenance of increased 
physical activity [21]. There is evidence in the gerontology literature that home-based 
exercise interventions may improve disability in older people with frailty [22]. However, 
research is needed to evaluate the benefits of a pragmatic, progressive home-based 
exercise programme tailored to the needs of people living with frailty and CKD. 
 
As recommended by the Medical Research Council (MRC) guidance for developing and 
evaluating complex interventions [23], pilot studies should be used to address key 
uncertainties prior to the definitive evaluation of complex interventions. Given the 
uncertainties previously described, a pilot randomised controlled trial (RCT) of a home-
based exercise programme for pre-frail and frail older adults with CKD is necessary. This will 
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inform the design of a large-scale RCT that investigates the effect of a home-based exercise 
intervention on physical function, frailty status, fall concern, activities of daily living, 
symptom-burden and HRQOL in pre-frail and frail older adults with CKD. The 2013 SPIRIT 
guidelines [24,25] will be used as the framework for reporting the EX-FRAIL CKD trial 
protocol. 
 
Objectives 
A pilot RCT will be performed that aims to: 
1. Evaluate rate of participant recruitment, intervention adherence, outcome measure 
completion and attrition.  
2. Qualitatively explore the acceptability of the randomisation procedure, outcome 
measures and, in the intervention arm, a progressive home-based exercise 
programme and identify areas requiring adaptation for a definitive RCT. 
3. Estimate the standard deviation of walking speed in pre-frail and frail patients with 
CKD to allow sample size estimation for a definitive RCT. 
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METHODS AND ANALYSIS 
Design 
The EX-FRAIL CKD trial is a two-arm parallel group pilot RCT. Outcome assessments will be 
performed at baseline and 12 weeks’ post-randomisation. A nested-qualitative study will be 
performed following completion of 12-week follow-up visits to explore participant 
perceptions of the study and, where applicable, the study intervention.  
 
Study Setting 
Participants will be recruited from outpatient clinics at Lancashire Teaching Hospitals NHS 
Foundation Trust (LTHTR), East Lancashire Teaching Hospitals NHS Trust and Blackpool 
Teaching Hospitals NHS Foundation Trust. The regional nephrology service operates a ‘hub 
and spoke’ model, accordingly participants attending clinics at sites other than LTHTR are 
still under the care of the LTHTR nephrology service. 
 
Inclusion Criteria 
Patients aged 65 years old with CKD G3b-5 (not receiving dialysis or received a kidney 
transplant) identified as at least ‘vulnerable’ using the Clinical Frailty Scale (score 4) are 
eligible for participation [26]. The Clinical Frailty Scale is a 9-point scale that provides 
definitions for levels of frailty and has good diagnostic accuracy for identifying patients with 
advanced CKD at risk of frailty [26,27]. It has been adopted as a frailty screening measure 
within usual care at LTHTR and is used by clinicians and clinical nurse specialists in 
outpatient clinics. Using a Clinical Frailty Scale score 4 within the inclusion criteria will 
maximise the likelihood of pre-frail and frail patients being approached for study 
involvement. Patients must also be able to give informed consent. 
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Exclusion Criteria 
1. In accordance with the American College of Sport’s Medicine [28]: 
 Unstable Angina or recent (within the last 3 months) myocardial infarction. 
 Uncontrolled arrhythmias. 
 Persistent uncontrolled hypertension (systolic blood pressure >180 mmHg or 
diastolic blood pressure >110 mmHg). 
2. Recent (within the last 3 months) stroke or transient ischaemic attack. 
3. Registered blind. 
4. Unable to mobilise independently. 
5. Receiving palliative care for advanced terminal cancer. 
6. Recently (within the last 12 months) enrolled in a structured exercise programme (e.g. 
cardiac rehabilitation) prescribed by a health professional. 
7. Anticipated to commence dialysis or receive a renal transplant within the next 3 months. 
8. Insufficient understanding of the English language to complete study questionnaires or 
follow advice within the exercise programme guidebook. 
9. Clinical and/or research team consider participation in the exercise programme unsafe. 
 
Timeline 
Figure 1 illustrates the participant flow through the study. Patients will be screened by 
members of the clinical team (based on age, CKD stage and Clinical Frailty Scale score). 
Patients aged 65 years with CKD G3b-5 and a Clinical Frailty Scale score 4 will be given a 
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participant information sheet. Patients will then be telephoned to establish if they are 
interested in participating and to ensure eligibility. Patients will be offered an appointment 
with the Chief Investigator, at least 24 hours following the telephone call, to obtain written 
informed consent to participate in the study.  
 
Our previous study demonstrated that a Clinical Frailty Scale score 4 had a sensitivity and 
specificity for identifying frailty of 1.00 and 0.55, respectively [27]. Given the risk of false 
positives, we considered it prudent to perform a more objective frailty assessment to 
ensure that only patients with pre-frailty or frailty underwent randomisation. The Frailty 
Phenotype (FP) is a well-studied method to diagnose physical frailty in CKD populations 
[2,5]. The FP includes 5 components, as detailed in Table 1 [2]. Frailty is diagnosed if an 
individual is assessed as having 3 components and pre-frailty if an individual has 1 or 2 
components [2]. The FP is not routinely performed in clinical practice and therefore can only 
be performed following study consent. Participants will have a FP assessment pre-
randomisation and will be withdrawn from the study if they are categorised as robust (i.e. 
not pre-frail or frail). This eventuality will be explained to patients prior to study consent. 
Participants categorised as pre-frail or frail will complete all outcome assessments as 
detailed in Table 2 and then be randomised to exercise or usual care groups. Follow-up 
outcome assessments will be performed 12-weeks post-randomisation. A group of 
participants will be invited to participate in semi-structured interviews following 12-week 
follow-up assessments (or following a participant’s decision to stop the exercise 
programme). 
 
Sample Size  
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We aim to recruit 40 participants to allow for a dropout rate (that includes participants 
categorised as robust using the FP) of up to 50% and still provide sufficient data to assess 
study feasibility and estimate the standard deviation of walking speed to inform the sample 
size calculation for a definitive RCT [18,22,29,30]. Semi-structured interviews will be 
conducted with a purposively selected group of participants, from both study arms, 
considering age, gender and frailty status. A pragmatic sample size of 12-14 participants will 
be recruited to this nested qualitative study.  
 
Allocation and Blinding 
Participants will be randomised in a 1:1 ratio to either the intervention or usual care. A 
central, concealed web-based randomisation process (www.sealedenvelope.com) will be 
performed in blocks of 4. Stratification will be limited to one factor, FP status, leaving 2 
strata, i.e. pre-frailty and frailty [31]. This will ensure that both groups contain similar 
proportions of pre-frail and frail participants. Participants cannot be blinded to the outcome 
of randomisation due to the nature of the intervention. Furthermore, outcome assessors 
will not be blinded to the outcome of randomisation as this pilot study does not aim to 
evaluate intervention effectiveness. Blinding of outcome assessors will be performed if a 
definitive RCT is considered feasible.  
 
Intervention Development 
The EX-FRAIL CKD exercise programme is a 12-week progressive, multi-component home-
based exercise programme. It was developed through review of international guidance and 
systematic reviews that evaluated exercise interventions in CKD and older adult 
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populations. A 2014 systematic review demonstrated that exercise training is associated 
with improved health outcomes in adults with CKD [15]. However, most studies evaluated 
interventions in adults with dialysis-dependent CKD and mostly aerobic exercise 
interventions [15]. The authors recommended further evaluation in non-dialysis populations 
and further analysis of resistance training and multi-component interventions [15]. Several 
systematic reviews have demonstrated that frail older adults benefit from exercise 
programmes and reported multi-component exercise programmes (involving combinations 
of strength, aerobic and balance training) were often effective [18,32,33]. A 2012 Cochrane 
review determined that both multi-component group exercise and home-based exercise 
reduce the rate of falls in older adults [34]. Furthermore, a systematic review of home-
based exercise programmes suggested that there is preliminary evidence that home-based 
exercise interventions may improve disability in older adults with moderate frailty [22]. The 
American College of Sports Medicine and American Heart Association Guidelines highlight 
the importance of physical activity being increased gradually in older adults, particularly 
those that are very deconditioned [35]. Additionally, the guidelines recommend that older 
adults who reduce their sedentary behaviour, even if not to the level recommended, still 
attain health benefits [35]. 
 
Intervention Description 
Participants randomised to the intervention will receive an individual exercise education 
session delivered by a physiotherapist experienced in exercise prescription. Participants will 
be provided information about the potential benefits of physical activity for their general 
health and well-being. They will subsequently receive instruction on how to complete the 
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exercises within the exercise programme safely and effectively. The exercises will be 
demonstrated to participants by a physiotherapist. The participants will then be asked to 
practice the exercises under supervision to ensure appropriate technique. If a participant is 
unable to perform a specific exercise, for example due to a functional limitation, an 
alternative will be provided that focuses on the same muscle groups. Furthermore, if a 
participant is unable to complete the proposed number of repetitions, the participant will 
be advised to perform a lower number of repetitions initially. This approach reflects exercise 
prescription in clinical practice and should increase the feasibility and safety of the exercise 
programme. 
 
Table 3 demonstrates the six exercises within the programme and details the progressions 
for each exercise. Participants categorised as frail will initially be advised to perform each 
exercise at level 1, whereas participants categorised as pre-frail will be advised to perform 
each exercise at level 2, unless the physiotherapist determines that it would be unsafe for 
an individual participant to perform a specific exercise at this level. Participants will receive 
education on how to use the Borg rating of perceived exertion [36] and will be advised to 
perform exercise 1 at a light intensity (Borg score <12) and exercises 2-6 at a moderate 
intensity (Borg score 12-16). Participants will be asked to gradually increase physical activity 
levels so that they ultimately perform three exercise sessions at home per week, with each 
session lasting approximately 30-45 minutes. Participants will be provided an exercise 
guidebook comprising written guidance on each exercise with accompanying photographs 
of models demonstrating the exercises.  
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Participants will be encouraged to complete an exercise diary. The diary prompts 
participants to document each exercise session including when they exercised, if they 
completed all exercises, the duration to complete the full exercise session and their Borg 
rating of perceived exertion for each exercise completed. Participants randomised to the 
intervention will receive weekly telephone calls from the physiotherapist or a specialist 
trainee in renal medicine who has clinical and research experience with patients living with 
frailty and CKD. To enhance intervention fidelity, a telephone pro forma will be used that 
prompts a review of the participants exercise diary, exercise technique, any problems 
(including symptoms, falls and healthcare episodes), an exploration of any participant 
uncertainties about the exercise programme and goal-setting for the following week. The 
physiotherapist and specialist trainee will discuss the outcomes of telephone calls, as a 
further safeguard of intervention fidelity. The telephone calls will be used to provide 
ongoing encouragement and to advise on exercise progression. If participants can perform 
exercises 2-6 comfortably (Borg score <12), the physiotherapist or specialist trainee will 
discuss exercise progression with the participant. If required, participants will be offered 
additional educational sessions during the 12-week intervention period to ensure safe 
exercise technique when progressing to more difficult exercise levels. Figure 2 illustrates the 
exercise intervention logic model and Table 4 summarises the intervention using the 
Template for Intervention Description and Replication (TIDieR) checklist [37]. 
 
Patient and Public Involvement 
The study was presented to the LTHTR Research Development Group, which includes lay 
members. Feedback from this meeting led to the adoption of a study design that included a 
nested qualitative interview study. The proposed study was also presented to members of a 
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local kidney patient charity, discussed in a patient focus group, supported by funding 
received from National Institute of Health Research (NIHR) Research Design Service, and 
with the LTHTR Lay Research Group, which is a group of local lay representatives. The study 
team were encouraged by positive feedback received on proposed study visits, outcome 
assessments and the exercise programme, including the burden of the intervention. 
 
Primary Feasibility Outcome Measures 
Primary feasibility outcome measures will be assessed as recommended by the CONSORT 
randomised pilot and feasibility trial guidelines [38]. The proportion of patients attending 
nephrology clinics that are eligible for study consent and the proportion of eligible patients 
subsequently recruited will be recorded. Reasons for ineligibility and non-consent will be 
recorded. In the intervention arm, adherence will be assessed by telephoning participants 
weekly to review the preceding week’s exercise activity and by reviewing participant 
exercise diaries at the end of the study period. Reasons for non-adherence will be 
documented. The proportion of participants who complete all outcome measures and who 
are lost to follow-up will be assessed. Reasons for failure to complete outcome measures 
and for study withdrawal will be recorded. 
 
Using a predetermined topic guide, the specialist trainee will conduct semi-structured face-
to-face interviews with participants. The interviews aim to explore the acceptability of the 
randomisation procedure, outcome measures and, in the intervention arm, a progressive 
home-based exercise programme. Perceived safety and barriers to participation will be 
explored. The interviews will be conducted in a private environment at the NIHR Lancashire 
Clinical Research Facility. Interviews will be audio recorded using a digital recorder with the 
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participant’s consent and will last approximately 30-60 minutes. Interviews will be 
transcribed verbatim. 
 
A ‘stop’, ‘change’ and ‘go’ approach to progression criteria will be used as described in the 
literature [39], with qualitative data used to identify areas for adaptation for a definitive RCT 
if required. Table 5 details the study progression criteria. 
 
Secondary Outcome Measures 
1. Physical Function 
Walking speed is independently associated with all-cause mortality in adults with CKD [40]. 
Walking speed will be assessed using infrared timing gates (Brower Timing System 2012, 
Brower Timing Systems, Draper, UT, USA). Participants will be asked to walk 15 feet at their 
normal walking pace on two occasions, using their usual walking aid if applicable. The 
fastest of two assessments will be used for analysis. A meaningful change in walking speed 
has been described as 0.05 metres per second [41,42]. 
 
The Short Physical Performance Battery (SPPB) comprises a group of measures of lower 
extremity function that together can be used to generate a composite score between 0 and 
12 [43]. SPPB score is associated with mortality in adults with CKD [44]. A minimally significant 
change in SPPB has been reported as 0.5 points [41,42]. The measures included in the SPPB 
are:  
 Five chair stands: timed standing from a chair at a standardised height five times as quickly 
as able.  
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 Balance testing: stand in three positions with increasing difficulty (standing with feet side 
by side, in a semi-tandem position and in a full tandem position) for 10 seconds in each 
position. 
 Walking speed: timed walking 8 feet at usual pace. 
 
2. Frailty  
As described earlier and detailed in Table 1, the FP can be used to diagnose pre-frailty and 
frailty [2], which are associated with adverse outcomes in CKD populations [6-11]. Studies 
have not evaluated the change in frailty status following exercise interventions in CKD 
populations. However, McAdams-DeMarco et al demonstrated an improvement in Frailty 
Phenotype score of 0.3 points following transplantation [45].  
 
3. Activities of Daily Living  
The Barthel Index evaluates independence with 10 activities of daily living to generate a score 
between 0 and 100 [46]. Higher scores indicate greater independence.  
 
4. Falls  
The Falls Efficacy Scale-International (FES-I) tool will be used to assess fall concern [47,48]. It 
is a self-report questionnaire that asks individuals to rate their fall concern for 16 situations 
on a four-point scale. The answers are totalled to provide a cumulative score between 16 and 
64. A score between 16 and 19 indicates low fall concern, between 20 and 27 moderate fall 
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concern and between 28 and 64 high fall concern. The number of falls within the preceding 6 
months will also be recorded.  
 
5. Symptom-Burden 
The Palliative Care Outcome Scale-Symptoms RENAL (POS-S RENAL) will be used to assess 
symptom burden [49]. The POS-S RENAL questionnaire asks individuals to report 17 
symptoms that may have affected them over the preceding week and to indicate to what 
extent. Each symptom is scored and scores totalled to create a symptom-burden score with 
higher scores representing greater symptom-burden.  
 
6. HRQOL 
The Short Form-12v2 (SF-12) comprises 12 questions that are used to assess HRQOL [50,51]. 
The answers are used to produce an 8-scale profile of health and well-being and to generate 
physical and mental health summary measures. Higher SF-12 scores represent better HRQOL. 
The proposed minimal important difference for SF-12 summary scales is 3 T-score points [52].  
 
Data Management  
All electronic study data will be recoded on a secure, password-protected database on the 
LTHTR server. The server is only be accessible using password-protected user profiles on 
LTHTR computers. Participant names and hospital identification numbers will not be 
recorded on this database; participants will be identified by a study-specific participant 
number. There will not be a formal data monitoring committee. However, data will be 
managed in accordance with the LTHTR Information Governance Policy. 
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Analysis Plan  
As recommended by the 2010 CONSORT guidelines [38], feasibility quantitative outcome 
measures will be reported descriptively with 95% confidence intervals. This will include the 
proportion of eligible patients and recruited participants, participants who adhere to the 
intervention, participants who complete all outcome assessments and participants lost to 
follow-up. Secondary outcome measures will also be reported descriptively with 95% 
confidence intervals. The standard deviation of walking speed will be estimated for both 
trial arms to inform the sample size calculation for a definitive RCT. SPSS software (version 
25, IBM Corp) will be used for statistical analysis. 
 
Qualitative data will be analysed using thematic analysis whereby narrative segments will 
first be coded and then translated into more abstract themes in an iterative manner [53]. 
NVivo software (version 12.5.0, QSR International) will be used to support analysis. Two 
members of the researcher team will compare themes to ensure all codes are represented. 
Qualitative and quantitative findings will be linked using a triangulation approach as 
described by Farmer et al [54] to provide a more comprehensive understanding of trial and 
intervention acceptability. 
 
Adverse Events 
Serious adverse events are defined as any episode during the study period that requires 
inpatient hospitalisation, results in persistent/significant disability, is life threatening or 
results in death. All adverse events will be discussed with the medically-trained Chief 
Investigator who will assess seriousness and causality. All adverse events will be reported to 
the study sponsor and all suspected unexpected serious adverse reactions reported to the 
The EX-FRAIL CKD Trial 
 22 
regional ethics committee. The trial will be stopped prematurely if three or more suspected 
unexpected serious adverse reactions occur. 
 
Study Steering Committee 
A study steering committee will provide scientific, ethical and financial oversight of research 
activity. The committee comprises clinicians, physiotherapists, academics, a study sponsor 
representative and a patient representative. Meetings will be held during before, during and 
on completion of the study. The patient representative will be remunerated as 
recommended by INVOLVE. 
 
Ethics and Dissemination 
Study ethical approval has been granted by the North West Greater Manchester East 
Research Ethics Committee (reference 18/NW/0211) and the National Health Service (NHS) 
Health Research Authority (project reference 244772). The LTHTR Centre for Health 
Research and Innovation accepted the role and responsibilities of study sponsorship. The 
study is subject to the LTHTR Internal Research and NIHR audit programmes to ensure all 
research activities are performed in accordance with the international standards of Good 
Clinical Practice, United Kingdom clinical trials legislation and trust policies. The trial is 
registered with the International Standard Randomised Controlled Trial Number Registry 
(ISRCTN87708989). Protocol amendments approved by the Research Ethics Committee/NHS 
Health Research Authority will be communicated with the study sponsor, study team and, 
where necessary, the trial registry. 
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The study dataset will not be made publicly available as it may be possible to identify 
participants from interview transcripts and as this pilot study does not aim to use 
quantitative data to demonstrate intervention effectiveness. The study team aim to publish 
the findings in a peer-reviewed journal and present the results at national and international 
conferences. A summary of findings will be provided to participants, a local kidney patient 
charity and the funding body.  
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DISCUSSION  
To our knowledge, the EX-FRAIL CKD trial is the first pilot RCT of a progressive home-based 
exercise intervention specifically designed for pre-frail and frail older adults with CKD. Given 
the uncertainties around recruitment rates, intervention adherence and outcome measure 
acceptability, it is necessary to perform a pilot study prior to proceeding with a full-scale 
trial. These uncertainties have been considered during study design, though amendments 
may be required to maximise the success of a multi-centre RCT.  
 
This study’s strengths include the use of a validated frailty screening measure [27] to assist 
participant recruitment and, during baseline assessment, the use of the reference standard 
for diagnosing physical frailty, i.e. the FP [2], to determine suitability for randomisation. This 
methodology will minimise the number of robust individuals approached for study consent 
and ensure that only pre-frail and frail participants receive the intervention, thereby 
strengthening any conclusions that can be made following study completion. Furthermore, 
the nested qualitative study will complement quantitative data analysis by exploring the 
acceptability of the randomisation procedures, outcome measures and intervention, thus 
identifying areas for adaptation in a definitive RCT. An acknowledged limitation is that semi-
structured interviews will be completed by a researcher involved in delivery of the study 
intervention, which may influence participant responses. However, the participants will be 
encouraged to give honest responses by reinforcing that the study objectives include to 
explore the acceptability of the study and identify areas requiring adaptation for a definitive 
RCT. For pragmatic reasons, patients that decline to participate in the study will not be 
invited to participate in an interview. However, participants that decide to stop exercising 
earlier than planned will be invited to participate in an interview to explore their experience 
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of the study. Furthermore, participants’ rationale and motivation for enrolling in the study 
will be explored during interviews. 
 
Home-based exercise programmes have been performed safely in frail older adults [22], 
however, perceived safety concerns (e.g. fall concerns) may influence participant adherence 
to the exercise programme. Participants randomised to the intervention arm will receive 
exercise education from a physiotherapist experienced in exercise prescription. Moreover, 
the exercise programme will be delivered in a graded and progressive manner with the use 
of weekly telephone calls that ensure safe exercise practices, explore participant 
uncertainties and provide ongoing support. We hope that the above will minimise 
participant concerns, therefore maximising participant adherence to the exercise 
programme.  
 
The EX-FRAIL CKD trial aims to inform the design of a definitive multi-centre RCT that 
explores the benefits of a progressive, multi-component home-based exercise programme. 
If a definitive RCT demonstrates improvements in the physical function of participants, 
associated improvements in mobility, fall concern, independence, symptom-burden and 
HRQOL are anticipated, supporting the case for a home-based exercise programme within 
routine clinical care. 
 
Trial Status 
The study opened in August 2018 and the first participant was recruited in November 2018. 
Data collection was completed in December 2019. 
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TABLES 
Table 1. The Frailty Phenotype. 
Frailty Phenotype Component Measure 
Unintentional Weight Loss 10 pounds or 5% body weight over the preceding 12 months. 
Weakness Hand grip strength will be assessed in the seated position with the elbow positioned at 
90 degrees, supported by the arm of a chair, and with a hand-grip dynamometer (Takei 
5101 GRIP-A dynamometer, Takei Scientific Inst. Co. Ltd., Niigata, Japan) supported by 
the assessor. Both arms will be examined with the highest score from three efforts from 
each side used for analysis. The body mass index and gender stratified hand grip strength 
cut-offs proposed by Fried et al are used to define weakness [2]. 
Slowness Walking speed (15 feet) will be assessed as outlined in the section titled ‘Physical 
Function’. The height and gender stratified walking speed cut-offs proposed by Fried et al 
are used to define slowness [2]. 
Low Physical Activity A modified version of the Minnesota Leisure Time Questionnaire [55] will be used to 
assess physical activity. Low physical activity is defined as <383 kcal/wk for men and <270 
kcals/wk for women [2]. 
Self-perceived Exhaustion The CES-D Scale will be used to assess self-perceived exhaustion [56]. Participants will be 
read the following statements: (1) I felt that everything I did was an effort. (2) I could not 
get going. Participants will then be asked, ‘How often in the last week did you feel this 
way?’ and provided the following scale: 0 = rarely or none of the time, 1 = some of the 
time, 2 = moderate amount of the time, 3 = most of the time. Self-perceived exhaustion 
is defined as an answer 2 for either statement [2]. 
Frailty is diagnosed if 3 or more frailty components are present. 
Pre-frailty is diagnosed if 1 or 2 frailty components are present. 
kcal/wk, Kilocalories per week; CES-D, Center for Epidemiological Studies Depression. 
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Table 2. Schedule of Assessments 
Assessment Time 
Screening Baseline Follow-Up 
Clinical Frailty Scale X   
Clinical Characteristics X X  
Weight, Height, HR, BP  X X 
Laboratory Variables X X  
Frailty Phenotype   X X 
SPPB  X X 
Barthel Index  X X 
SF-12  X X 
FES-I  X X 
POS-S RENAL  X X 
Semi-structured Interview   X 
HR, Heart Rate; BP, Blood Pressure; SPPB, Short Physical Performance Battery; SF-12, Short Form-12v2; FES-I, 
Falls Efficacy Scale-International; POS-S RENAL, Palliative Care Outcome Scale-Symptoms RENAL. 
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Table 3. The EX-FRAIL CKD Exercise Programme. 
Exercise Level 1 Level 2 Level 3 Level 4 
1. Walking Walk for 1 minute Walk for 2 minutes Walk for 10 minutes Walk for 15 minutes 
2. Lower leg 
extension 
Seated leg extension* Seated leg raise* Seated weighted 
(0.5kg) leg raise* 
Seated weighted 
(1kg) leg raise* 
3. Bilateral calf 
raises 
Seated calf raises* Standing calf raises 
placing hands on 
secure surface* 
Standing calf raises 
placing finger tips 
on secure surface* 
Standing calf raises* 
4. Sit to stand Sit to stand using 
arms to assist* 
Sit to stand without 
using arms to assist* 
Sit to stand holding 
0.5kg weights* 
Sit to stand holding 
1kg weights* 
5. Wall/table 
push up 
Wall push up** Wall push up* Table push up** Table push up* 
6. Marching  Marching whilst 
seated* 
Marching whilst 
standing with hands 
on secure surface* 
Marching whilst 
standing* 
Stair step* 
*3 sets of 10 repetitions; **3 sets of 5 repetitions. 
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Table 4. TIDier Checklist. 
 
Item  
1. Brief name The EX-FRAIL CKD Exercise Programme 
2. Rationale Described in ‘Introduction’ and section titled ‘Intervention Development’ 
3. Materials Exercise guidebook, exercise diary and wrist/ankle weights. 
4. Procedures Described in section titled ‘Intervention Description’ and ‘Participant 
Timeline’. 
5. Provider Exercise programme education will be delivered by a physiotherapist 
experienced in exercise prescription. Weekly telephone calls will be 
performed by the physiotherapist or specialist trainee with relevant 
experience. 
6. Modes of delivery Face-to-face exercise education session followed by weekly telephone calls.  
7. Location Exercise education sessions will be delivered in a private room at NIHR 
Lancashire Clinical Research Facility. All exercise sessions will be completed in 
the participant’s own home.  
8. Frequency and 
duration 
All participants will have an exercise education session lasting approximately 
60 minutes. Participants will aim to perform three exercise sessions at home 
per week, lasting approximately 30-45 minutes each. 
9. Tailoring  Initial exercise level will be determined by frailty status, unless the 
physiotherapist determines otherwise due to safety concerns. An alternative 
exercise will be provided if a participant is unable to perform a specific 
exercise as originally intended. 
10. Modifications Cannot be described until study completion. 
11. Adherence and 
fidelity: planned 
Exercises will be delivered as described in the exercise guidebook. If 
modification is needed, the participant (and study team) will be provided 
additional documentation. Adherence will be assessed during telephone calls 
and review of the participant’s exercise diary. Outcomes of telephone calls 
will be discussed to maintain fidelity.  
12. Adherence and 
fidelity: actual 
Cannot be described until study completion. 
NIHR, National Institute of Health Research. 
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Table 5. Progression Criteria. 
 
Progression Criteria Stop/Go Thresholds 
Eligibility STOP: <5% of patients eligible 
GO: >10% of patients eligible 
Recruitment STOP: <10% of eligible patients recruited 
GO:  >30% of eligible patients recruited 
Exercise Adherence 
(defined as 2 sessions/week) 
STOP: <30% adherence  
GO: >70% adherence 
Outcome Measure Completion 
(not including lost to follow up) 
STOP: <70% outcome measure completion 
GO: >80% outcome measure completion 
Lost to Follow-Up 
(including withdrawn and lost) 
STOP: >50% lost to follow-up 
GO: <25% lost to follow-up 
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FIGURE LEGENDS 
 
Figure 1. Study Flow Diagram. 
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Figure 2. Exercise Intervention Logic Model. 
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